Results of Treatment of Chronic Hepatitis C with Recombinant Interferon Alpha (rINF-alpha) in Pre- and Post-transplant Patients.
- Author:
Hyung Wook KIM
1
;
Bum Soon CHOI
;
Mi Kyung KIM
;
Byung Whoa HA
;
Joo Hyun PARK
;
Chul Woo YANG
;
Yong Soo KIM
;
Suk Young KIM
;
Euy Jin CHOI
;
Yoon Sik CHANG
;
In Sung MOON
;
Yong Bok KOH
;
Byung Kee BANG
Author Information
1. Department of Internal Medicine, Kangnam St Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea. nephron@cmc.cuk.ac.kr
- Publication Type:Original Article
- Keywords:
Kidney transplantation;
Chronic hepatitis C;
Interferon
- MeSH:
Anemia, Hemolytic;
Dialysis;
Follow-Up Studies;
Hepacivirus;
Hepatitis C, Chronic*;
Hepatitis, Chronic*;
Humans;
Injections, Subcutaneous;
Interferon-alpha*;
Interferons*;
Kidney Failure, Chronic;
Kidney Transplantation;
Liver Diseases;
Peritoneal Dialysis;
Renal Dialysis;
Renal Insufficiency;
Ribavirin;
RNA;
Transplantation;
Waiting Lists
- From:The Journal of the Korean Society for Transplantation
2001;15(2):194-202
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: Recombinant Interferon-alpha (rIFN-alpha) treatment is effective in treating chronic hepatitis C in the patients with end stage renal disease, and is also effective in preventing reactivation of hepatitis C virus (HCV) after renal transplantation. We here report our experience of rIFN-alpha treatment in renal transplant recipients and dialysis patients awaiting transplantation. METHODS: Total nine patients were enrolled. Four patients (2 Hemodialysis patients, 2 Peritoneal dialysis patients) were on waiting lists for renal transplantation and five patients were renal transplant recipients. All the patients were HCV antibody and HCV RNA positive with elevated ALT more than normal limit for at least 6 months. Five renal transplant recipients had stable renal function for at least 6 months. rIFN-alpha at a dose of 3 million units was administered by subcutaneous injection three times a week for 6 months. Two renal transplant recipient received rIFN-alpha in combination with ribavirin (600 mg orally per day). RESULTS: At the end of treatment, the rate of virological response (negative conversion of HCV RNA) was 67% (6/9 cases), and biochemical response (normalized ALT) was 88% (8/9 cases). The virological responders showed sustained loss of HCV RNA (sustained virological response 67%). and 7 out of 8 biochemical responder had normal ALT during follow-up period (sustained biochemical response 77%). Two patients who showed negative conversion of HCV RNA in the pre- renal transplantation period showed sustained loss of HCV RNA and normal ALT over post-renal transplantation period. There was no irreversible renal failure and acute rejection episode in renal transplant recipients during treatment of rIFN-alpha except one recipient with reversible and mild renal dysfunction, but two case of combination therapy of rIFN-alpha and ribavirin had hemolytic anemia. CONCLUSION: The rIFN-alpha therapy in pre-transplant patients may appear to exert a beneficial effect of the liver disease following renal transplantation and irreversible renal failure does not develop in renal transplant recipients.
